Christine Geiger, NP
Family · Williamsville, NYNPI 1366967614
Payments from drug & device makers
Across 84 payments — averaging $47.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Novartis$295
- AbbVie$228
- Regeneron Healthcare Solutions, Inc.$139
- VYNE Pharmaceuticals Inc.$122
- Tandem Diabetes Care, Inc.$119
- plus $360 from 12 others
What the payments were for
- Speaking & faculty fees$1,37534%
- Travel & lodging$1,02326%
- Food & beverage$1,52538%
- Education$812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $2,741 |
| Novartis | 32 | $295 |
| AbbVie | 13 | $228 |
| Regeneron Healthcare Solutions, Inc. | 3 | $139 |
| VYNE Pharmaceuticals Inc. | 4 | $122 |
| Tandem Diabetes Care, Inc. | 1 | $119 |
| Pfizer | 3 | $80 |
| Incyte Corporation | 2 | $46 |
| Galderma Laboratories, L.p. | 3 | $45 |
| Arcutis Biotherapeutics, Inc. | 2 | $32 |
| Biofrontera Inc. | 2 | $27 |
| Organon | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,004 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 11 | $841 |
| Clobetasol Propionate | 18 | $664 |
| Ketoconazole | 31 | $586 |
| Metronidazole | 11 | $469 |
| Clindamycin Phosphate | 14 | $390 |
| ValacyclovirValacyclovir Hcl | 15 | $290 |
| Triamcinolone Acetonide | 22 | $250 |
| Doxycycline Hyclate | 24 | $230 |
| Hydrocortisone | 21 | $198 |
| Hydroxyzine Hcl | 12 | $111 |
| Prednisone | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other family in Williamsville
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.